In vitro and in vivo efficacy of the triazole TAK-187 against Cryptococcus neoformans

Antimicrobial Agents and Chemotherapy

Volumn 42, Issue 10, 1998, Pages 2630-2632

  Schell, Wiley A ^a,b   Duboc De Almeida, Gisele Madeira ^d   Dodge, Richard K ^c   Okonogi, Kenji ^e   Perfect, John R ^a,b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DURHAM VA MEDICAL CENTER   (United States)

^c DUKE CANCER INSTITUTE   (United States)

^d UNIVERSITY OF SÃO PAULO   (Brazil)

^e TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2 [2 (2,4 DIFLUOROPHENYL) 2 HYDROXY 1 METHYL 3 (1H 1,2,4 TRIAZOL 1 YL)PROPYL] 4 [4 (2,2,3,3 TETRAFLUOROPROPOXY)PHENYL] 1,2,4 TRIAZOL 3(2H) ONE; FLUCONAZOLE; TRIAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC RESISTANCE; ARTICLE; CEREBROSPINAL FLUID EXAMINATION; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; DOSE RESPONSE; DRUG EFFICACY; FUNGICIDAL ACTIVITY; NONHUMAN; PRIORITY JOURNAL; RABBIT; TREATMENT PLANNING;

EID: 0344765508     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.42.10.2630     Document Type: Article

References (24)

1. Armengou, A., C. Porcar, J. Mascaro, and F. Garcia-Bragado. 1996. Possible development of resistance to fluconazole during suppressive therapy for AIDS-associated cryptococcal meningitis. Clin. Infect. Dis. 23:1337-1338.
2. Bennett ,J. E., W. Dismukes, R. J. Duma, G. Medoff, M. A. Sande, H. Gallis, J. Leonard, B. T. Fields, M. Bradshaw, H. Haywood, Z. A. McGee, T. R. Cate, C. G. Cobbs, J. F. Warner, and D. W. Alling. 1479. A comparison of amphotericin B alone and combined with flucytosine in the treatment ol cryptococcal meningitis. N. Engl. J. Med. 301:120-131.
3. Birley, H. D., E. M. Johnson, P. McDonald, C. Parry, P. B. Carey, and D. W. Warnock. 1995. Azole drug resistance as a cause of clinical relapse in AIDS patients with cryptococcal meningitis. Int. J. Sex. Transm. Dis. AIDS 6:353-355.
4. Bozzette, S. A., R. A. Larsen, and J. Chin. 1991. A placebo-controlled trial of maintenance therapy with fluconazole after treatment of cryptococca meningitis in the acquired immunodeficiency syndrome. N. Engl. J. Med. 324: 580-584.
5. Dismukes, W. E., G. Cloud, H. A. Gallis, T. M. Kerkering, G. Medoff, P. L. Craven, L. G. Kaplowitz, J. F. Fisher, C. R. Gregg, C. A. Bowles, S. Shadomy, A. M. Stamm, R. B. Diasio, L. Kaufman, S.-J. Soong, W. Blackwelder, and the National Institute of Allergy and Infectious Diseases Mycoses Study Group. 1987. Treatment of cryptococcal meningitis with combination amphotericin B and flucytosine for four as compared with six weeks. N. Engl. J. Med. 317:314-341.
6. Galgiani, J. N., M. S. Bartlett, M. A. Ghannoum, A. Espinel-Ingroff, M. V. Lancaster, F. C. Odds, M. A. Pfaller, M. G. Rinaldi, and T. J. Walsh. 1997. Reference method for broth dilution antifungal susceptibility testing of yeasts, p. 1-29. Approved standard 17-9. National Committee for Clinical Laboratory Standards, Wayne,. Pa.
7. Itoh, K. K. Okonogi, A. Tasaka, R. Hayashi, N. Tamura, N. Tsuchimori, T. Kitazaki, Y. Matsushita, and J. Obita. 1996. TAK-187, a new antifungal triazole: synthesis and antifungal activity, abstr. F74, p. 112. In Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy American Society for Microbiology, Washington, D.C.
8. Pappas, P. J. Perfect, H. Henderson, C. Kauffman, M. Saccente, D. Haas, G. Pankey, D. Lancaster, M. Holloway, G. Cloud, and W. Dismukes. 1997. Cryptococcosis in non-HIV infected patients: a multicenter survey, abstr. 128. Thirty-fifth Infectious Disease Society of America.
9. Perfect, J. R. 1990. Fluconazole therapy for experimental cryptococcosis and candidiasis in the rabbit. Rev. Infect. Dis. 12(Suppl. 3):299-302
10. Perfect, J. R., G. M. Cox, R. K. Dodge, and W. A. Schell. 1996. In vitro and in vivo efficacies of the azole SCH56592 against Cryptococcus neoformans. Antimicrob. Agents Chemother. 40:1910-1913.
11. Perfect, J. R. and D. T. Durack. 1982. Treatment of experimental cryptococcal meningitis with amphotericin B. 5-fluorocytosine and ketoconazole. J. Infect. Dis. 146:429-435.
12. Perfect, J. R. and D. T. Durack. 1985. Comparison of amphotericin B and N-D-ornithyl amphotericin B methyl ester in experimental cryptococcal meningitis and Candida albicans endocarditis with pyelonephritis. Antimicrob. Agents Chemother. 28:751-755.
13. Perfect, J. R., S. D. R. Lang, and D. T. Durack. 1980. Chronic cryptococcal meningitis a new experimental model in rabbits. Am. J. Pathol. 101:177-194.
14. Perfect, J. R., D. V. Savani, and D. T. Durack. 1986. Comparison of itraconazole and fluconazole in treatment of cryptococcal meningitis and Candida pyelonephritis in rabbits. Antimicrob. Agents Chemother. 29:579-583.
15. Perfect, J. R., and K. A. Wright. 1994. Amphotericin B lipid complex in the treatment of experimental cryptococcal meningitis and disseminated candidiasis. J. Antimicrob. Chemother. 33:73-81.
16. Perfect, J. R., K. A. Wright, M. M. Hobbs, and D. T. Durack. 1989. Treatment of experimental cryptococcal meningitis and disseminated candidiasis with SCH 39304. Antimicrob. Agents Chemother. 33:1735-1740.
17. Powderly, W. G., D. M. Finkelstein, J. Feinberg, P. Frame, W. He, C. van der Horst, S. L. Koletar, M. E. Eyster, J. Carey, H. Waskin, T. M. Hooton, N. Hyslop, S. A. Spector, and S. A. Bozzette. 1995. A randomized trial comparing fluconazole with clotrimazole troches tor the prevention of fungal infections in patients with advanced human immunodeficiency virus infection. N. Engl. J. Med. 332:700-705.
18. Powderly, W. G., M. S. Saag, G. A. Cloud, P. Robinson, R. Meyer, J. M. Jacobson, J. R. Graybill, A. M. Sugar, V. J. McAuliffe, S. E. Follansbee, C. U. Tuazon, J. J. Stern, J. Feinberg, R. Hafner, and W. E. Dismukes. 1992. A controlled trial of fluconazole or amphotericin B to prevent relapse of cryptococcal meningitis in patients with the acquired immunodeficiency syndrome. N. Engl. J. Med. 326:793-798.
19. Prugam, A., J. Dupouy-Camet, P. Blanche, J. P. Gangneux, C. Tourte-Schaefer, and D. Sicard. 1994. Increased fluconazole resistance of Cryptococcus neoformans isolated from a patient with AIDS and recurrent meningitis. Clin. Infect. Dis. 19:975-976.
20. Saag, M. S., W. G. Powderly, G. A. Cloud, P. Robinson, M. H. Grieco, P. K. Sharkley, S. E. Thompson, A. Sugar, C. U. Tuazon, J. F. Fisher, N. Hyslop, J. M. Jacobson, R. Hafner, and W. F. Dismukes 1992. Compansor of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. N. Engl. J. Med. 326:83-89.
21. Tasaka, A., T. Kitazaki, N. Tsuchimori, Y. Matsushita, R. Hayashi, K. Okonogi, and K. Itoh. 1997. Opticaly active antifungal azoles. VII. Synthesis and antifungal activity of stereoisomers of 2-[(1R,2R)-2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl) propyl]-4-[4-(2,2,3,3-tetrafluoropropoxy)phenyl]-3(2H,4H)-1,2,4-triazolone (TAK-198). Chem. Pharm. Bull. 45:321-326.
22. van der Horst, C. M. S. Saag, G. A. Cloud, R. J. Hamill, J. R. Graybill, D. Sobel, P. C. Johnson, C. U. Tuazon, T. Kerkering, B. L. Moskovitz, W. G. Powderly, and W. E. Dismukes. 1997. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. N. Engl. J. Med. 337:15-21.
23. Viard, J. P., C. Hennequin, N. Fortineau, N. Pertuiset, C. Rothschild, and H. Zylberberg. 1995. Fulminant cryptococcal infections in HIV-infected patients on oral fluconazole. Lancet 346:118.
24. Wright, K. A., J. R. Perfect, and W. Ritter. 1990. The pharmacokinetics of BAY R3783 and its efficacy in the treatment of experimental cryptococcal meningitis. J. Antimicrob. Chemother. 26:387-397.